These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25251069)

  • 21. Screening drugs for myocardial disease in vivo with zebrafish: an expert update.
    Zhao Y; Zhang K; Sips P; MacRae CA
    Expert Opin Drug Discov; 2019 Apr; 14(4):343-353. PubMed ID: 30836799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-impedance-based label-free technology for the identification of new drugs.
    Lundstrom K
    Expert Opin Drug Discov; 2017 Apr; 12(4):335-343. PubMed ID: 28276704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriate experimental approaches for predicting abuse potential and addictive qualities in preclinical drug discovery.
    Mead AN
    Expert Opin Drug Discov; 2014 Nov; 9(11):1281-91. PubMed ID: 25176123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.
    Gul S; Hadian K
    Expert Opin Drug Discov; 2014 Dec; 9(12):1393-404. PubMed ID: 25374163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral therapies for drug abuse.
    Carroll KM; Onken LS
    Am J Psychiatry; 2005 Aug; 162(8):1452-60. PubMed ID: 16055766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substance abuse in adolescents: a complex conundrum for the clinician.
    Greydanus DE; Patel DR
    Pediatr Clin North Am; 2003 Oct; 50(5):1179-223. PubMed ID: 14558685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing opioids that deter abuse.
    Raffa RB; Pergolizzi JV; Muñiz E; Taylor R; Pergolizzi J
    Pain Res Treat; 2012; 2012():282981. PubMed ID: 23213510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of high-content screening (HCS) technology and its importance to drug discovery.
    Fraietta I; Gasparri F
    Expert Opin Drug Discov; 2016; 11(5):501-14. PubMed ID: 26971542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
    Keck TM; John WS; Czoty PW; Nader MA; Newman AH
    J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurobiology of addiction. Toward the development of new therapies.
    Koob GF
    Ann N Y Acad Sci; 2000; 909():170-85. PubMed ID: 10911930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
    Struzyna LA; Watt ML
    Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction.
    Filip M; Zaniewska M; Frankowska M; Wydra K; Fuxe K
    Curr Med Chem; 2012; 19(3):317-55. PubMed ID: 22335511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in capillary electrophoresis and the implications for drug discovery.
    Ouimet CM; D'amico CI; Kennedy RT
    Expert Opin Drug Discov; 2017 Feb; 12(2):213-224. PubMed ID: 27911223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel methods and approaches to acute lymphoblastic leukemia drug discovery.
    Wei MC; Cleary ML
    Expert Opin Drug Discov; 2014 Dec; 9(12):1435-46. PubMed ID: 25212992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional genomic and high-content screening for target discovery and deconvolution.
    Heynen-Genel S; Pache L; Chanda SK; Rosen J
    Expert Opin Drug Discov; 2012 Oct; 7(10):955-68. PubMed ID: 22860749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yeast: bridging the gap between phenotypic and biochemical assays for high-throughput screening.
    Denny PW
    Expert Opin Drug Discov; 2018 Dec; 13(12):1153-1160. PubMed ID: 30326751
    [No Abstract]   [Full Text] [Related]  

  • 39. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.